- Home
- JELD vs ACRS Comparison
JELD vs ACRS Comparison
Compare JELD & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JELD
- ACRS
- Stock Information
- Founded
- JELD 1960
- ACRS 2012
- Country
- JELD United States
- ACRS United States
- Employees
- JELD N/A
- ACRS N/A
- Industry
- JELD Forest Products
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- JELD Basic Materials
- ACRS Health Care
- Exchange
- JELD Nasdaq
- ACRS Nasdaq
- Market Cap
- JELD 221.3M
- ACRS 230.8M
- IPO Year
- JELD 2017
- ACRS 2015
- Fundamental
- Price
- JELD $1.81
- ACRS $2.54
- Analyst Decision
- JELD Hold
- ACRS Strong Buy
- Analyst Count
- JELD 7
- ACRS 9
- Target Price
- JELD $4.61
- ACRS $9.25
- AVG Volume (30 Days)
- JELD 1.9M
- ACRS 1.5M
- Earning Date
- JELD 11-03-2025
- ACRS 11-06-2025
- Dividend Yield
- JELD N/A
- ACRS N/A
- EPS Growth
- JELD N/A
- ACRS N/A
- EPS
- JELD N/A
- ACRS N/A
- Revenue
- JELD $3,304,951,000.00
- ACRS $15,742,000.00
- Revenue This Year
- JELD N/A
- ACRS N/A
- Revenue Next Year
- JELD $2.44
- ACRS N/A
- P/E Ratio
- JELD N/A
- ACRS N/A
- Revenue Growth
- JELD N/A
- ACRS N/A
- 52 Week Low
- JELD $1.82
- ACRS $1.05
- 52 Week High
- JELD $11.66
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- JELD 11.86
- ACRS 59.58
- Support Level
- JELD $2.12
- ACRS $2.38
- Resistance Level
- JELD $2.65
- ACRS $2.61
- Average True Range (ATR)
- JELD 0.24
- ACRS 0.24
- MACD
- JELD -0.10
- ACRS 0.00
- Stochastic Oscillator
- JELD 0.57
- ACRS 70.83
About JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential single and multi-family homes and non-residential buildings. The firm's operating segments are North America, Europe, and Australasia. It generates a majority of its revenue from North America.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.